Alkaline Phosphatase and Hyperphosphatasemia in Vitamin D Trial in Healthy Infants and Toddlers
Authors' conclusion
Approximately 5% of infants had hyperphosphatasemia at 12 months, but <1% at 24 months. ALP concentrations and hyperphosphatasemia were associated with sex, anthropometry, and bone mineralization. Infections did not contribute to hyperphosphatasemia.
Study context
- Population
- Healthy infants and toddlers who received vitamin D3 10 or 30 µg daily from age 2 weeks to 2 years, with alkaline phosphatase (ALP) data at 12 and/or 24 monthsgirls 51.9%
- Participants
- 813 infants
- Comparison
- Boys vs girls; vitamin D3 10 vs 30 µg daily
- Primary endpoint
- ALP concentrations and prevalence of hyperphosphatasemia, and their association with vitamin D, growth, infections and bone parameters
- Follow-up
- 12 and 24 months
Primary result
As reported in the abstract
ALP concentration · 12 months
P = 0.02
- Prevalence of hyperphosphatasemia (ALP > 1000 U/L) at 12 months
- 5.3%
- Prevalence of hyperphosphatasemia (ALP > 1000 U/L) at 24 months
- 0.6%
Further findings
ALP concentration at 24 months
- Lower than at 12 months, median [IQR]
- 240 [202-284]; P < .001
- No sex difference
Original publication
Alkaline Phosphatase and Hyperphosphatasemia in Vitamin D Trial in Healthy Infants and Toddlers. J Clin Endocrinol Metab. Published 17 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →